Dr. Reddy’s  Key Near Term Earnings Catalysts: Nirmal Bang
People chat in the lobby of Innovation Plaza building, on Dr. Reddy’s Laboratories Ltd. campus in Hyderabad. (Photographer: Prashanth Vishwanathan/Bloomberg)

Dr. Reddy’s Key Near Term Earnings Catalysts: Nirmal Bang

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

Consistent delay in the approval of its complex generic pipeline (Copaxone and Nuvaring) and underperformance in Q3 FY21 have led to the Dr. Reddy’s Laboratories Ltd. stock price correct meaningfully from its highs in the recent past.

As we move forward, we foresee important catalysts that should help drive strong growth in FY22 earnings.

  • The company has applied for emergency authorization of its in-licensed Covid-19 vaccine from Drugs Controller General of India and is currently awaiting approval.
  • The company had launched generic Kuvan in tablet form in October 2020 in the U.S., while it is yet to launch the powder version which has a 70% volume share and should help the company garner a larger share.

Click on the attachment to read the full report:

Nirmal Bang Dr Reddys Laboratories-Company Update-10 March 2021.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.